EISAI
Eisai is a human health care company that provides products and services to its patients and their families under any healthcare system. Eisai specializes in the integrated pharmaceutical business that operates in business groups it focuses on oncology and neurology, dementia-related diseases and neurodegenerative diseases. The company was founded in 1941 and headquartered in Tokyo, Japan.
EISAI
Industry:
Biotechnology Health Care Health Insurance Pharmaceutical
Founded:
1941-12-06
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Website Url:
http://www.eisai.co.jp
Total Employee:
10001+
Status:
Active
Contact:
81-3-3817-3700
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Apache Global Site Tag
Similar Organizations
Advantage Risk Management
Advantage Risk Management is a mental health care company that provides comprehensive mental health services for companies.
Eisai Europe
Eisai Europe is a human health care company that provides products and services to its patients.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Jaber Ibn Hayyan Pharmaceutical
Jaber Ibn Hayyan Pharmaceutical manufactures drugs like anti-biotic, non-antibiotic , topical, oral and others.
UNI PHARMA
Unipharma is to provide healthcare products and outstanding services for both pharmaceutical and animal healthcare products.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2010-01-07 | AkaRx | AkaRx acquired by Eisai | 255 M USD |
| 2007-03-22 | Morphotek | Morphotek acquired by Eisai | 325 M USD |
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-08-09 | LIFENET INSURANCE COMPANY | Eisai investment in Post-IPO Equity - LIFENET INSURANCE COMPANY | 300 M JPY |
| 2022-01-27 | Ractigen Therapeutics | Eisai investment in Series A - Ractigen Therapeutics | 30 M USD |
| 2021-09-09 | Neuroglee Therapeutics | Eisai investment in Series A - Neuroglee Therapeutics | 10 M USD |
| 2021-05-04 | ÅŒURA | Eisai investment in Series C - ÅŒURA | 100 M USD |
| 2021-04-05 | Allm | Eisai investment in Series A - Allm | 5.6 B JPY |
| 2020-12-03 | Neuroglee Therapeutics | Eisai investment in Pre Seed Round - Neuroglee Therapeutics | 2.3 M USD |
| 2020-11-05 | Unlearn.AI | Eisai investment in Series A - Unlearn.AI | 3 M USD |
| 2020-04-10 | Darmiyan | Eisai investment in Seed Round - Darmiyan | 6.43 M USD |
| 2019-12-12 | Numab | Eisai investment in Series B - Numab | 22 M CHF |
| 2019-05-09 | Allm | Eisai investment in Corporate Round - Allm | N/A |
Newest Events participated
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-27 | Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership |
Official Site Inspections
http://www.eisai.co.jp Semrush global rank: 333.99 K Semrush visits lastest month: 181.62 K
Unable to get host informations!!!
